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Introduction
cohorts were terminated after 21 st week after ACF procedure. The third cohort (n=10/SH groups, n=90/ACF groups) was left free of any procedures and served for a survival analysis till 52 nd week. The investigation conformed to the NIH Guide for the care and use of laboratory animals (NIH Publication No. 1996) , Animal protection law of the CR (311/1997) and was approved by the ethics committee of IKEM.
Echocardiography and hemodynamics
Animals were anesthetized with ketamine/midazolam i.p. injection (50mg/5mg/kg). Echocardiography was performed using 7.5 MHz probe (Vivid System 5, GE, Indianapolis, USA), end-systolic and end-diastolic sizes of the left ventricle together with wall thicknesses were measured in parasternal long (PLAX) and short (PSAX) axis projection, the size of the right ventricle in apical four chamber projection (A4C). Invasive hemodynamics evaluation was performed by F2 Millar catheter inserted into aorta and LV via the carotid artery. After the hemodynamic assessment, rats were killed by exsanguination, coronary tree was flushed with ice-cold cardioplegic solution and LV free wall samples were instantly flash-frozen in liquid nitrogen for biochemical analyses or used for mitochondrial function assessment or electron microscopy.
Myocardial biochemistry and ultrastructure
Myocardial ATP content was measured in flash-frozen tissue using HPLC [24] . The content of total and phosphorylated form of AMPK was assessed by the Western blot as described before [25] . Briefly, phosphorylated AMPK (pAMPK) was assessed using rabbit anti pAMPK antibody (Cell Signaling), total AMPK (tAMPK) using goat anti alpha1+alpha2 AMPK antibody (Santa Cruz). Acetyl-CoA carboxylase (ACC) is a downstream target for AMPK. The ratio of phosphorylated ACC (pACC) at Ser-79 to total ACC (tACC) is a robust assay of AMPK activation [26] . Phosphorylated ACC was quantified by the Western blot using phospho-specific rabbit antibodies against Ser-79 (Abcam). Total ACC was measured by IRDye-800-conjugated Streptavidine (Rockland). The mitochondrial respiratory-chain complexes CI-CV were quantified by the Western blot [27] . Specific activities of cytochrome c oxidase and citrate synthase were determined spectrophotometrically in the myocardial homogenate [28] . Myocardial ultrastructure was studied on LV samples fixed in glutaraldehyde, post-fixed with osmium tetroxide, stained with uranyl acetate and examined with transmission electron microscope (Philips CM100, FEI, formerly Philips EO, Netherlands) with 25000x magnification. Image area occupied by mitochondria, myofibrils and cytoplasm was quantified by grid point-counting method [29] and expressed as percentage.
Mitochondrial function
In the myocardial tissue homogenate, maximal ADP-stimulated oxidative capacity of mitochondria was determined as oxygen consumption rate with palmitoylcarnitine (12.5μM)+malate (3mM)+glutamate (10mM)+succinate (10mM) using high-resolution oxygraph-2k (OROBOROS, Austria) [30] . Respiratory control index that indicates the tightness of the coupling between respiration and phosphorylation was calculated as the ratio of glutamate+malate+ADP (1.5mM) respiration without and with oligomycin (6μM).
Myocardial gene expression
Total RNA was isolated by RNeasy Micro Kit (QIAGEN Inc., Valencia, CA, USA), 200 ng of total RNA was used for the amplification procedure and 1.5 μg of amplified RNA was hybridized on the chip according to the manufacturer´s procedure. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
Microarray analysis:
The raw data (.TIFF image files) was analyzed using beadarray package [31] of the Bioconductor [32] within the R environment (http://www.r-project.org) [33] . The gene set enrichment analysis (GSEA) was performed on gene sets defined by the KEGG pathways [34] . Lists of genes assigned to the KEGG pathways were downloaded from the KEGG (release 48.0).
Systemic and organ metabolic analyses
MET serum level was checked in tail-vein serum at 11 th week in ACF+MET (n=12) and SH+MET (n=18) groups. The MET level was measured using HPLC method with separation on silica column (ThermoQuest, Runcorn, UK) with a spectrophotometric detection. Oral glucose tolerance tests (oGTT) were performed in all groups at 20 th week using an oral glucose load of 300mg/100g BW as gavage after overnight fasting. Serum glucose was measured by the glucose-oxidase assay, serum FFAs were determined by a colorimetric assay (Roche, Mannheim, Germany). Serum insulin was determined using the rat insulin ELISA kit (Mercodia, Uppsala, Sweeden). Tissue triglycerides were measured in liquid nitrogenpowdered tissues after chloroform/methanol extraction using the enzymatic assay (PlivaLachema, Brno, Czech Republic), used also for serum triglycerides. The glycogen in the heart was measured after KOH extraction [35] . Glycogen synthesis and glucose oxidation in the heart and muscle -Basal and insulinstimulated 14 C-glucose incorporation into glycogen and CO 2 was determined ex vivo in isolated diaphragm [36] . Similarly, 1-mm thick, cross-sectional slices of the left ventricle at mid-papillary level were analyzed [37] . Fatty acid oxidation in the heart -Fatty acid oxidation in the heart tissue muscles and heart slices was determined by measuring the incorporation of 14 C-palmitic acid into CO 2 [38] .
Statistics
Two-way ANOVA with Bonferroni post hoc adjustment was used to compare the effects of surgery and metformin treatment. Survival analysis was performed using Gehan-BreslowWilcoxon test. P-values < 0.05 were considered statistically significant. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
Results

MET serum assessment
MET serum level at 11 th week was 2.2 ± 0.7 μg/ml (13 ± 4.15 nmol/ml) in ACF+MET group (n=12) and 1.9 ± 2.7 μg/ml (11.6 ± 16.1 nmol/ml) in SH+MET group (n=18) (p=0.68), being within the range of human therapeutic dose (corresponding to daily 2000 mg MET dose in an average adult) [39] and within the range of no observable adverse effect for rats [40] .
Organ morphometry, hemodynamics and echocardiography All groups had similar body weights and tibial lengths. Both ACF groups had marked heart hypertrophy ( Table 1 ) and increased lung weight/body weight indicating pulmonary congestion. ACF animals had a depletion of intraabdominal adipose tissue in epididymal and perirenal fat body. ACF animals had elevated left ventricular end-diastolic pressure (LVEDP), indicating decompensated heart failure but still preserved LV contractility (dP/dt max ) and relaxation (dP/dt min , tau constant). The systolic duration/cycle length ratio was higher in both ACF groups. No effect of MET on hemodynamics was observed ( Table 2) . ACF animals had marked enlargement of both ventricles (Table 3) , a twofold increase in stroke volume and cardiac output due to fistula and diminished left ventricular fractional shortening and ejection fraction. Both LV anterior and posterior walls in all groups showed similar thicknesses. No effect of MET on echocardiographic parameters was observed.
Metabolic assessment
Glucose and glycogen metabolism-When assessed using oral glucose tolerance test (oGTT), all the groups showed similar glucose levels throughout the test and preserved postprandial glycemic regulation (Fig. 1A, B) . ACF animals had lower insulin levels at the baseline (Fig.  1C ) and a trend towards lower levels post-load (Fig. 1D) . Myocardium of all animals showed similar contents of glycogen ( Fig. 2D ) and the rate of glycogen synthesis (data not shown). Myocardial glucose oxidation was significantly lower in both ACF groups and metformin treatment induced further lowering (Fig. 2E) , independently of ACF procedure. ACF animals had a lower rate of glycogen synthesis in the skeletal muscle (diaphragm) than SHAM ( Fig.  3A ) but all groups had a similar insulin-stimulated increment of glycogen synthesis (Fig. 3B ), which is a measure of skeletal muscle insulin sensitivity [36, 41] . There was no difference in skeletal muscle (diaphragm) glucose oxidation (data not shown). Lipid metabolism-Serum and liver triglycerides were similar in all groups ( Fig. 2A, C) . In contrast, myocardial triglyceride content was markedly decreased in ACF animals (Fig. 2B) . ACF animals had increased serum FFA concentration in fasted state and even more after glucose loading compared to sham-operated animals. MET treatment reduced FFA levels in both metformin-treated groups compared to placebo (Fig. 1E, F) . Myocardial palmitate oxidation was reduced in ACF+PL group by 37% (p<0.001) compared to SH+PL. MET treatment (ACF+MET) increased myocardial palmitate oxidation to the level similar in SH+PL group (Fig. 2F ).
Mitochondrial function
Cytochrome c oxidase (CIV) and citrate synthase activities (Fig. 5D , E) and the protein content of mitochondrial respiratory chain complexes CI-V ( A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
reflecting that the resting respiration was largely intact and coupled. Analysis of myocardial ATP content showed similar level of ATP (Fig. 5A ) indicating undisturbed resting energetic state in HF animals. Electron microscopy showed no apparent structural abnormalities and the proportions occupied by myofibrils (my), mitochondria (mi) and cytosol were similar in all groups (Fig. S3 in online supplement).
AMP-activated protein kinase (AMPK) signalling
To characterize the activity of the AMPK-regulatory cascade, total content and phosphorylation of both AMPK and its target, acetyl-CoA carboxylase (ACC), were assessed by the Western blot. At the level of AMPK, ACF animals showed significantly higher contents of both total (tAMPK) and phosphorylated AMPK (pAMPK) than sham groups. However, the ratio between phosphorylated and total AMPK (pAMPK/tAMPK) was similar independent of ACF procedure or metformin treatment (Fig. 4 A-C) . At the level of ACC, no differences neither in total ACC (tACC), phosphorylated ACC (pACC) nor in pACC/tACC ratio were observed between groups (Fig. 4 D-F) . These data suggest a modest upstream AMPK activation due to ACF procedure, but the absence of a significant functional consequence at the level of the downstream target of AMPK neither due to ACF procedure nor to MET treatment.
Myocardial gene expression analysis
Out of 23401 detected transcripts, we observed no difference between ACF+MET and ACF+PL, which was in striking contrast to fistula-induced transcriptional changes (ACF+PL vs. SH+PL), where 128 transcripts were differentially expressed (99 upregulated and 29 downregulated, Storey's q-value < 0.05 and two-fold or greater change in intensity). Fig. S1 in online supplement depicts a heatmap with all differentially expressed transcripts. KEGG pathway analysis revealed the downregulation of pathways involved in fatty acid metabolism in response to ACF (Fig. S2 in online supplement) .
Survival
None of the control animals died throughout the study. First deaths in ACF groups occurred between 10 th and 15 th week and 77.2% of ACF+PL (80.5% of ACF+MET) animals were dead by the end of the study. Median survival was 45.5 weeks in ACF+PL group and 44.5 weeks in ACF+MET group. MET therapy had no effect on survival in ACF animals (Fig. 6) . A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
Discussion
The study shows that chronic volume overload-induced heart failure (HF) is associated with lower glycogen synthesis in the skeletal muscle (diaphragm), lower heart triglyceride content, higher plasmatic free fatty acids (FFA), lower plasmatic insulin level and depressed myocardial glucose and palmitate oxidation. Long-term administration of antihyperglycemic drug metformin (MET) normalized elevated FFA, further decreased myocardial glucose oxidation and increased myocardial palmitate oxidation, but had no effect on myocardial AMPK activation, ATP content, mitochondrial function or morphology. No relevant improvement in cardiac performance or long-term survival was observed in MET-treated HF animals. Despite several recent studies reported beneficial effect of MET in other non-diabetic HF models [42] [43] [44] , our study indicates that this improvement is not common to all HF forms. Decreased cellular energetic charge [10] and/or AMPK activation by MET may be required for improvement of cardiac performance in HF. Conversely, prolonged exposure of symptomatic HF animals to high-dose MET led to no increase in mortality, supporting safety of MET use in diabetic HF.
Peripheral and systemic MET effects
At the systemic level, MET lowered basal and postprandial circulating FFA due to increased FFA utilization and perhaps also due to diminished FFA release from adipose tissue because of known inhibitory effects of MET on catecholamine-stimulated lipolysis [45] . ACF rats had a depletion of intraabdominal adipose tissue, indicative of enhanced fat mobilization due to neurohumoral activation from HF, but MET did not reverse fat depletion. MET also had no effect on insulin-mediated glycogen synthesis in skeletal muscle, which is a measure of insulin sensitivity.
Cardiac effects of MET
In the heart, MET treatment significantly increased the palmitate oxidation that was attenuated in the ACF+PL group. Diminished oxidation of long chain fatty acids and downregulation of enzymes of fatty acid oxidation in the heart have been repeatedly described both in HF patients [1] and in animal HF models [3, 4, 46] including rats with ACF [5, 47, 48] , reflecting probably a reactivation of fetal-like gene transcriptional programme [2, 4] . Whether this change is adaptive or not is still discussed. Functional consequences of drug-induced reversal of diminished FA oxidation are unknown. Our study indicates that drug-induced enhancement of FA oxidation has a neutral effect on survival and cardiac function in HF due to volume overload supporting the view that diminished myocardial FA oxidation does not play the causal role in HF progression. Similar findings were reported also in pacing-induced HF, where long-term therapy with PPAR-α agonist fenofibrate increased FA utilization, but did not delay the HF onset [49] . MET had no effect on mitochondrial respiratory function, myocardial gene transcription profile, and the size of mitochondrial compartment within the cardiomyocyte, speaking against the specific activation of mitochondrial biogenesis [50] . Myocardial gene expression profile in MET-treated ACF animals was unchanged, indicating non-genomic mechanisms involved in FA oxidation increase after MET. Moravec et al. had showed that isolated cardiac mitochondria from ACF rats have impaired activation and transport of palmitoyl group across outer mitochondrial membrane (via palmitoyl-CoA synthase and carnitine-palmitoyl-CoA transferase-1), leading to attenuated oxidation of palmitate, but preserved oxidation of palmitoyl-carnitine [5] . Kinetic studies indicated that the cooperation between those two enzymes deteriorates with increasing FFA concentrations. Thus, the improvement of FA oxidation after MET treatment in ACF group can be a consequence of the mere reduction of circulating FFAs in serum [5] . The apparent opposite responses of myocardial fatty acid oxidation and glucose oxidation can be explained either by A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law. a metformin-induced inhibition of glycolysis [11] or by a Randle effect-increased fatty acid oxidation increases the concentration of acetyl-CoA in the Krebs cycle leading to an inhibition of pyruvate dehydrogenase with a subsequent inhibition of glycolysis and glucose oxidation [51] .
Comparison to other HF studies
The absence of benefit of MET on cardiac function or survival in ACF-induced HF is in contrast with other recently published studies in other HF models. Gundewar et al. [44] examined the effect of very low dose MET (125 µg/kg/day i.p.) on cardiac function and survival in mice subjected to LAD ligation. MET extended the survival at 4 weeks by 47%, improved LV remodeling and corrected MI-induced defects in mitochondrial respiration and ATP synthesis. Despite the administered MET-dose (per kg BW/day) was lower by three orders of magnitude than in our study (i.e. 300 mg MET/kg/day) or than is normally used in humans, authors were able to detect increased phosphorylation of AMPK, eNOS and increased expression of PGC-1α in the heart. In another study, Sasaki et al. examined the effect of 4-week oral MET therapy (100 mg/kg/day) in the tachypacing-HF model in dogs. Compared to placebo, MET improved LV ejection fraction, slowed HF progression and decreased myocardial apoptosis via AMPK-dependent mechanism [42] . Xiao et al. [52] documented an improvement of cardiac diastolic function upon metformin treatment in pressure overload HF model. Dose used in this study (200mg/kg/day) was similar to ours.
Lack of the protecting effect of MET in volume-overload HF model
Mechanism of MET action is still incompletely understood. One possibility expects an activation of AMP-activated protein kinase (AMPK) that turns on energy-providing and turns off energy-consuming metabolic pathways [9, 53] , but non-AMPK dependent MET effects have also been described [10, 11] . The reason why MET therapy provided no hemodynamic or survival benefit in ACF-induced HF model in contrast to other models is not clear. We excluded the possibility of underdosing or poor absorption, because MET serum levels were adequate and within the therapeutic range observed in humans [40] . The effect of MET could be affected by varying intracellular import, which depends on the capacity of organic cation transporter (OCT-1). Genetic polymorphisms in OCT-1 gene (SCL22A1) were shown to affect a clinical response to MET therapy in humans [54] . In our study, MET administration had no effect on either mitochondrial functions or on mitochondrial and ultrastructural morphology. Ultrastructural morphology was similar among groups regardless of ACF procedure or MET treatment, despite a marked increase in heart weights in both ACF groups. This can be explained by an increase in myocyte width and length [55] . An increase in both phosphorylated (pAMPK) and total (tAMPK) forms of AMP-activate protein kinase was observed with a preserved pAMPK/tAMPK ratio. On the level of acetyl-CoA carboxylase (ACC), which is a direct downstream target of AMPK, no differences in phosphorylated form of ACC (pACC), total ACC (tACC) nor in the pACC/tACC ratio occurred. This observation suggests a modest upstream AMPK activation due to ACF procedure, but the absence of a significant functional consequence at the level of the downstream target of AMPK. Insufficient AMPK activation could potentially explain the lack of MET benefit in our model. AMPK catalytic subunits are highly conserved, so inter-species structural differences are unlikely to explain the inability of MET to activate AMPK in our protocol. An absence of AMPK activation in our ACF-induced HF model could be explained by an unaltered myocardial ATP level in this model. Model-specific differences thus seem to provide an acceptable explanation. The cardioprotective effect of metformin can be at least partially ascribed to the attenuation of cardiac fibrosis [52] , but compared to pressure overload, volume overload is not associated with increased myocardial fibrosis [22, 23] . Compared to the study A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
of Gundewar [44] , we did not find any increase in AMPK activity or decrease in oxygen consumption rate or respiratory control index. It appears that in contrast to pressure overload, volume overload does not sufficiently alter resting mitochondrial function [23] and thus it may lack the substrate for metformin action. Finally, no insulin resistance was observed in our volume-overload HF model, so the lack of insulin resistance might also implicate a missing substrate for MET action. Despite all these specifics of the model, we should be aware that HF is a non-uniform syndrome and it should be studied in subsets. Volume overload is a clinically important condition and its most common form (mitral insufficiency) often complicates other heart diseases and independently increases mortality [56] .
Metabolic abnormalities in ACF HF model
ACF-induced HF model showed several specific features. Despite gene expression analysis showed an extensive downregulation of β-oxidation pathway and several respiratory chain components in ACF, ATP-generating capacity of mitochondria in surplus of oxygen and substrates was preserved. This might be explained by a redundancy in enzyme activities and longer half-life [4, 57] . Myocardial ATP content, presented for the first time in this model, was also normal. This is in agreement with the study from Marcil et al. [58] who showed normal myocardial oxidative capacity in compensated ACF-induced HF (15 th week), but marked sensitivity of the heart to hypoxia, indicating preserved ATP levels at rest, but attenuated energetic reserve during increased stress. Low myocardial triglyceride content in ACF hearts, also reported for the first time, is probably related to limited reesterification of triglycerides due to low availability of NADPH [59] and this abnormality was unchanged by MET therapy. Although a number of works described connections between elevated levels of FFAs [16] and insulin resistance [15, 60] in HF, muscle insulin sensitivity, measured as insulin-induced increment of glycogen synthesis [36, 41] , was preserved in ACF, making perhaps this model less prone to benefits of MET. Interestingly, fasting and postprandial insulinaemia were actually lower in ACF than in control animals. Pancreatic hypoperfusion or negative effects of chronically elevated FFAs on pancreatic β-cell secretory function might be responsible for this phenomenon [61] .
In conclusion, the presented study shows that long-term MET therapy in rats with HF due to volume-overload decreases circulating FFA, decreases myocardial glucose oxidation and increases myocardial palmitate oxidation, but these effects have neutral impact on cardiac performance and survival in HF. Recently reported cardioprotective effects of MET may not be universal to all forms of HF and may require AMPK activation or ATP depletion. Prolonged exposure of a large group of severely symptomatic HF animals to high-dose MET led to no apparent increase in mortality, which provides robust data to the toxicology of MET [40] and supports its safe use in HF patients with diabetes. Triglycerides in the heart, C. Triglycerides in the liver, D. Glycogen in the heart, E.
14 Cglucose oxidation in the heart, F.
14 C-palmitate oxidation in the heart. White: controls with placebo (SH+PL), Hatched white: controls with MET (SH+MET), Grey: aorto-caval fistula with placebo (ACF+PL), Hatched grey: aorto-caval fistula with MET (ACF+MET). Results are expressed as means ± S.E.M. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law. A c c e p t e d M a n u s c r i p t Licenced copy. Copying is not permitted, except with prior permission and as allowed by law. A c c e p t e d M a n u s c r i p t
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